Advanced Proteome Therapeutics Corporation (APTCF)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | - USD | -100.0% |
| 2022 | 1.48 Million USD | -49.7% |
| 2021 | 2.95 Million USD | 110.89% |
| 2020 | 1.4 Million USD | 29.66% |
| 2019 | 1.08 Million USD | 0.13% |
| 2018 | 1.08 Million USD | 11.42% |
| 2017 | 969.34 Thousand USD | 59.19% |
| 2016 | 608.91 Thousand USD | 15.21% |
| 2015 | 528.52 Thousand USD | -58.17% |
| 2014 | 1.26 Million USD | 33.56% |
| 2013 | 946.03 Thousand USD | 83.38% |
| 2012 | 515.88 Thousand USD | 95.28% |
| 2011 | 264.18 Thousand USD | 26.54% |
| 2010 | 208.77 Thousand USD | 0.0% |
| 2009 | 208.76 Thousand USD | 8.25% |
| 2008 | 192.86 Thousand USD | 10.72% |
| 2007 | 174.19 Thousand USD | 14852.53% |
| 2006 | 1165.00 USD | -99.15% |
| 2005 | 137.19 Thousand USD | -95.84% |
| 2004 | 3.29 Million USD | -1.21% |
| 2003 | 3.34 Million USD | -67.34% |
| 2002 | 10.22 Million USD | -8.98% |
| 2001 | 11.23 Million USD | 0.39% |
| 2000 | 11.19 Million USD | -10.89% |
| 1999 | 12.56 Million USD | 13.71% |
| 1998 | 11.04 Million USD | 661.37% |
| 1997 | 1.45 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | - USD | 0.0% |
| 2023 Q1 | 1.25 Million USD | -15.87% |
| 2023 Q2 | 1.45 Million USD | 16.31% |
| 2023 FY | - USD | -100.0% |
| 2023 Q3 | 84.49 Thousand USD | -94.19% |
| 2023 Q4 | - USD | -100.0% |
| 2022 FY | 1.48 Million USD | -49.7% |
| 2022 Q3 | 2.01 Million USD | 33.95% |
| 2022 Q4 | 1.48 Million USD | -26.14% |
| 2022 Q2 | 1.5 Million USD | -31.31% |
| 2022 Q1 | 2.18 Million USD | -25.99% |
| 2021 Q2 | 1.52 Million USD | -9.81% |
| 2021 Q4 | 2.95 Million USD | -22.16% |
| 2021 Q3 | 3.79 Million USD | 149.72% |
| 2021 Q1 | 1.68 Million USD | 20.29% |
| 2021 FY | 2.95 Million USD | 110.89% |
| 2020 Q3 | 1.11 Million USD | 1.38% |
| 2020 FY | 1.4 Million USD | 29.66% |
| 2020 Q1 | 1.01 Million USD | -6.53% |
| 2020 Q2 | 1.09 Million USD | 8.47% |
| 2020 Q4 | 1.4 Million USD | 26.14% |
| 2019 FY | 1.08 Million USD | 0.13% |
| 2019 Q1 | 1.2 Million USD | 11.91% |
| 2019 Q3 | 1 Million USD | 3.01% |
| 2019 Q4 | 1.08 Million USD | 7.74% |
| 2019 Q2 | 974.38 Thousand USD | -19.38% |
| 2018 Q4 | 1.08 Million USD | 12.55% |
| 2018 Q1 | 910.46 Thousand USD | -6.08% |
| 2018 Q3 | 959.58 Thousand USD | -28.22% |
| 2018 FY | 1.08 Million USD | 11.42% |
| 2018 Q2 | 1.33 Million USD | 46.84% |
| 2017 FY | 969.34 Thousand USD | 59.19% |
| 2017 Q3 | 893.55 Thousand USD | 11.26% |
| 2017 Q4 | 969.34 Thousand USD | 8.48% |
| 2017 Q2 | 803.1 Thousand USD | 5.96% |
| 2017 Q1 | 757.96 Thousand USD | 24.48% |
| 2016 Q2 | 499.01 Thousand USD | 0.69% |
| 2016 Q4 | 608.91 Thousand USD | 19.27% |
| 2016 FY | 608.91 Thousand USD | 15.21% |
| 2016 Q1 | 495.61 Thousand USD | -6.23% |
| 2016 Q3 | 510.53 Thousand USD | 2.31% |
| 2015 FY | 528.52 Thousand USD | -58.17% |
| 2015 Q1 | 599.08 Thousand USD | -52.59% |
| 2015 Q3 | 540.81 Thousand USD | 1.65% |
| 2015 Q4 | 528.52 Thousand USD | -2.27% |
| 2015 Q2 | 532.01 Thousand USD | -11.2% |
| 2014 Q1 | 946.04 Thousand USD | 0.0% |
| 2014 Q2 | 2.63 Million USD | 178.09% |
| 2014 Q3 | 1.97 Million USD | -24.87% |
| 2014 FY | 1.26 Million USD | 33.56% |
| 2014 Q4 | 1.26 Million USD | -36.08% |
| 2013 Q3 | 881.47 Thousand USD | 27.94% |
| 2013 Q4 | 946.03 Thousand USD | 7.32% |
| 2013 Q2 | 689 Thousand USD | 22.88% |
| 2013 FY | 946.03 Thousand USD | 83.38% |
| 2013 Q1 | 560.7 Thousand USD | 8.69% |
| 2012 FY | 515.88 Thousand USD | 95.28% |
| 2012 Q1 | 256.6 Thousand USD | -2.87% |
| 2012 Q2 | 304.84 Thousand USD | 18.8% |
| 2012 Q3 | 503.14 Thousand USD | 65.05% |
| 2012 Q4 | 515.88 Thousand USD | 2.53% |
| 2011 FY | 264.18 Thousand USD | 26.54% |
| 2011 Q4 | 264.18 Thousand USD | 6.09% |
| 2011 Q3 | 249.02 Thousand USD | -1.25% |
| 2011 Q2 | 252.17 Thousand USD | 0.1% |
| 2011 Q1 | 251.91 Thousand USD | 20.67% |
| 2010 Q3 | 211.08 Thousand USD | 1.75% |
| 2010 Q4 | 208.77 Thousand USD | -1.09% |
| 2010 FY | 208.77 Thousand USD | 0.0% |
| 2010 Q1 | 274.78 Thousand USD | 31.62% |
| 2010 Q2 | 207.46 Thousand USD | -24.5% |
| 2009 Q3 | 229.86 Thousand USD | 29.95% |
| 2009 Q2 | 176.87 Thousand USD | -10.76% |
| 2009 Q4 | 208.76 Thousand USD | -9.18% |
| 2009 Q1 | 198.19 Thousand USD | 2.77% |
| 2009 FY | 208.76 Thousand USD | 8.25% |
| 2008 Q3 | 175.59 Thousand USD | -1.72% |
| 2008 FY | 192.86 Thousand USD | 10.72% |
| 2008 Q1 | 227.44 Thousand USD | 30.57% |
| 2008 Q2 | 178.67 Thousand USD | -21.44% |
| 2008 Q4 | 192.86 Thousand USD | 9.83% |
| 2007 Q3 | 170.24 Thousand USD | -21.9% |
| 2007 Q1 | 409.99 Thousand USD | 35092.45% |
| 2007 Q2 | 217.98 Thousand USD | -46.83% |
| 2007 Q4 | 174.19 Thousand USD | 2.32% |
| 2007 FY | 174.19 Thousand USD | 14852.53% |
| 2006 FY | 1165.00 USD | -99.15% |
| 2006 Q1 | 42.81 Thousand USD | -68.79% |
| 2006 Q2 | 40.48 Thousand USD | -5.44% |
| 2006 Q3 | 61.37 Thousand USD | 51.59% |
| 2006 Q4 | 1165.00 USD | -98.1% |
| 2005 Q3 | 3.36 Million USD | 1.5% |
| 2005 FY | 137.19 Thousand USD | -95.84% |
| 2005 Q1 | 3.17 Million USD | -3.82% |
| 2005 Q4 | 137.19 Thousand USD | -95.92% |
| 2005 Q2 | 3.31 Million USD | 4.4% |
| 2004 FY | 3.29 Million USD | -1.21% |
| 2004 Q4 | 3.29 Million USD | 1.46% |
| 2004 Q3 | 3.25 Million USD | 2.07% |
| 2004 Q2 | 3.18 Million USD | 3.07% |
| 2004 Q1 | 3.09 Million USD | -7.45% |
| 2003 Q1 | 10.12 Million USD | -0.96% |
| 2003 FY | 3.34 Million USD | -67.34% |
| 2003 Q2 | 3.21 Million USD | -68.27% |
| 2003 Q3 | 3.28 Million USD | 2.34% |
| 2003 Q4 | 3.34 Million USD | 1.55% |
| 2002 Q4 | 10.22 Million USD | -0.47% |
| 2002 FY | 10.22 Million USD | -8.98% |
| 2002 Q1 | 10.36 Million USD | -7.73% |
| 2002 Q2 | 10.24 Million USD | -1.2% |
| 2002 Q3 | 10.27 Million USD | 0.31% |
| 2001 Q4 | 11.23 Million USD | 3.53% |
| 2001 FY | 11.23 Million USD | 0.39% |
| 2001 Q2 | 10.39 Million USD | -4.83% |
| 2001 Q1 | 10.92 Million USD | -2.43% |
| 2001 Q3 | 10.85 Million USD | 4.42% |
| 2000 Q2 | 12.09 Million USD | 2.88% |
| 2000 Q1 | 11.75 Million USD | -6.39% |
| 2000 Q3 | 11.14 Million USD | -7.9% |
| 2000 FY | 11.19 Million USD | -10.89% |
| 2000 Q4 | 11.19 Million USD | 0.47% |
| 1999 FY | 12.56 Million USD | 13.71% |
| 1999 Q1 | 11.46 Million USD | 3.81% |
| 1999 Q4 | 12.56 Million USD | 3.52% |
| 1999 Q2 | 11.51 Million USD | 0.43% |
| 1999 Q3 | 12.13 Million USD | 5.36% |
| 1998 Q3 | 838.22 Thousand USD | 74.39% |
| 1998 Q1 | 994.1 Thousand USD | 0.0% |
| 1998 FY | 11.04 Million USD | 661.37% |
| 1998 Q2 | 480.67 Thousand USD | -51.65% |
| 1998 Q4 | 11.04 Million USD | 1217.93% |
| 1997 FY | 1.45 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | 100.0% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 100.0% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 100.0% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | 100.0% |
| Rebus Holdings, Inc. | 5.24 Million USD | 100.0% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 100.0% |
| Qrons Inc. | 1.48 Million USD | 100.0% |
| Adynxx, Inc. | - USD | NaN% |
| Neon Bloom, Inc. | 1.22 Million USD | 100.0% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 100.0% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | 100.0% |
| Skye Bioscience, Inc. | 14.07 Million USD | 100.0% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 100.0% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 100.0% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | 100.0% |
| SQZ Biotechnologies Company | 50.03 Million USD | 100.0% |
| Intellipharmaceutics International Inc. | 12 Million USD | 100.0% |
| Propanc Biopharma, Inc. | 3.85 Million USD | 100.0% |
| Mesoblast Limited | 188.44 Million USD | 100.0% |
| Marizyme, Inc. | 26.67 Million USD | 100.0% |
| Genus plc | 485 Million USD | 100.0% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 100.0% |
| Pharming Group N.V. | 244.07 Million USD | 100.0% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | 100.0% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | 100.0% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | 100.0% |
| ContraFect Corporation | 32.53 Million USD | 100.0% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | 100.0% |
| Sienna Biopharmaceuticals, Inc. | - USD | NaN% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | 100.0% |
| IMV Inc. | 37.93 Million USD | 100.0% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 100.0% |
| MultiCell Technologies, Inc. | 1617.67 USD | 100.0% |
| ONE Bio Corp. | 27.49 Million USD | 100.0% |
| Accustem Sciences Inc. | 1.07 Million USD | 100.0% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 100.0% |
| Arno Therapeutics, Inc. | - USD | NaN% |
| EV Biologics, Inc. | 2.11 Million USD | 100.0% |
| Q BioMed Inc. | 8.13 Million USD | 100.0% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 100.0% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | 100.0% |
| Biomind Labs Inc. | 1.49 Million USD | 100.0% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 100.0% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 100.0% |
| TetraLogic Pharmaceuticals Corporation | - USD | NaN% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 100.0% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | 100.0% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | 100.0% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | 100.0% |
| Curative Biotechnology, Inc. | 5.74 Million USD | 100.0% |
| GB Sciences, Inc. | 5.41 Million USD | 100.0% |
| Alpha Cognition Inc. | 7.16 Million USD | 100.0% |
| HST Global, Inc. | 593.59 Thousand USD | 100.0% |
| CSL Limited | 18.62 Billion USD | 100.0% |
| Wesana Health Holdings Inc. | 1.25 Million USD | 100.0% |
| Halberd Corporation | 728.71 Thousand USD | 100.0% |
| Enzolytics Inc. | 365.26 Million USD | 100.0% |
| Agentix Corp. | 2.51 Million USD | 100.0% |
| Resverlogix Corp. | 67.39 Million USD | 100.0% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | 100.0% |
| MetaStat, Inc. | - USD | NaN% |
| argenx SE | 444.95 Million USD | 100.0% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | 100.0% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 100.0% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 100.0% |
| GeneThera, Inc. | - USD | NaN% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | 100.0% |
| AVAX Technologies, Inc. | 3.99 Million USD | 100.0% |
| Zenith Capital Corp. | 27.56 Thousand USD | 100.0% |
| Genscript Biotech Corporation | 1.32 Billion USD | 100.0% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | 100.0% |
| Anthera Pharmaceuticals, Inc. | - USD | NaN% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | 100.0% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | 100.0% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | 100.0% |
| Kadimastem Ltd | 3.5 Million USD | 100.0% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | 100.0% |
| VitaSpring Biomedical Co. Ltd. | - USD | NaN% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 100.0% |
| BioStem Technologies, Inc. | 15.9 Million USD | 100.0% |
| Oncology Pharma Inc. | - USD | NaN% |
| Reve Technologies, Inc. | 464.69 Thousand USD | 100.0% |
| LadRx Corporation | 2.2 Million USD | 100.0% |
| Cell Source, Inc. | 15.8 Million USD | 100.0% |
| Regen BioPharma, Inc. | 5.45 Million USD | 100.0% |
| Regen BioPharma, Inc. | 5.45 Million USD | 100.0% |
| NovAccess Global Inc. | 7.86 Million USD | 100.0% |
| Affymax, Inc. | 8.87 Million USD | 100.0% |
| Itoco Inc. | 1.65 Million USD | 100.0% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | 100.0% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 100.0% |
| Mobile Lads Corp. | 1.31 Million USD | 100.0% |
| CytoDyn Inc. | 127.89 Million USD | 100.0% |
| Claritas Pharmaceuticals, Inc. | - USD | NaN% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | 100.0% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | 100.0% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 100.0% |
| SYBLEU INC | 681.41 Thousand USD | 100.0% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 100.0% |
| International Stem Cell Corporation | 5.27 Million USD | 100.0% |
| Bioxytran, Inc. | 3.24 Million USD | 100.0% |
| GlobeImmune, Inc. | - USD | NaN% |
| Predictive Technology Group, Inc. | - USD | NaN% |
| ProText Mobility, Inc. | 625.8 Thousand USD | 100.0% |
| Cardax, Inc. | - USD | NaN% |
| VG Life Sciences Inc. | 4.61 Million USD | 100.0% |
| Kaleido Biosciences, Inc. | - USD | NaN% |
| Advaxis, Inc. | 40.99 Million USD | 100.0% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 100.0% |
| RenovaCare, Inc. | - USD | NaN% |
| Regnum Corp. | 2.02 Million USD | 100.0% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | 100.0% |
| Neutra Corp. | 973.52 Thousand USD | 100.0% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 100.0% |
| PureTech Health plc | 125.58 Million USD | 100.0% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | 100.0% |
| IXICO plc | 1.9 Million USD | 100.0% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 100.0% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 100.0% |
| CSL Limited | 18.62 Billion USD | 100.0% |
| Cellectis S.A. | 249.36 Million USD | 100.0% |